Intermittent Fasting Shields Kidneys from Scarring by Halting Cell Aging
A 5:2 fasting regimen dramatically reduced kidney fibrosis in mice after injury by suppressing cellular senescence and inflammatory SASP signals.
Summary
Researchers at Pusan National University found that a 5:2 intermittent fasting protocol significantly reduced kidney fibrosis in mice following ischemia-reperfusion injury. The study showed that fasting suppressed key senescence markers (p21, Cdkn1a, Cdkn2a) and dampened the senescence-associated secretory phenotype (SASP), which includes pro-fibrotic cytokines like TGF-β, TNF-α, IL-6, IL-1α, and IL-1β. Fasting also restored metabolic regulators SIRT1, phosphorylated AMPK, and PGC-1α. These findings suggest intermittent fasting may offer a non-pharmacological strategy to prevent chronic kidney disease progression after acute kidney injury.
Detailed Summary
Acute kidney injury (AKI) is a common and serious condition that frequently progresses to chronic kidney disease through fibrosis — scarring driven in part by the accumulation of senescent cells. Finding non-drug interventions that can interrupt this process is a major goal in nephrology and longevity medicine.
This study used male C57BL/6 mice subjected to unilateral ischemia-reperfusion injury (IRI), a standard model of AKI. After surgery, mice assigned to intermittent fasting followed a 5:2 schedule — two 24-hour fasting periods per week — for eight weeks. Four groups were compared: sham surgery, fasting only, IRI only, and IRI plus fasting.
Two months post-surgery, mice in the IRI-only group developed pronounced tubulointerstitial fibrosis, a hallmark of maladaptive kidney repair. Strikingly, the IRI plus fasting group showed markedly reduced fibrosis. Molecular analysis revealed that fasting downregulated p21 protein and reduced transcript levels of Cdkn1a and Cdkn2a — two canonical markers of cellular senescence. Fasting also suppressed the SASP, a cocktail of pro-inflammatory cytokines (TNF-α, TGF-β, IL-6, IL-1α, IL-1β) secreted by senescent cells that perpetuate tissue damage and fibrosis.
Additionally, intermittent fasting restored expression of key metabolic regulators: SIRT1 (a longevity-associated deacetylase), phosphorylated AMPK (an energy-sensing kinase), and PGC-1α (a master regulator of mitochondrial biogenesis). This suggests fasting improves metabolic resilience alongside its anti-senescence effects.
While compelling, the study is limited to male mice and a single injury model, and the 5:2 fasting protocol's translation to human patients — especially those with existing kidney disease — requires careful clinical investigation. Still, this research adds mechanistic support for dietary interventions as adjuncts in AKI management.
Key Findings
- 5:2 intermittent fasting markedly reduced tubulointerstitial fibrosis 8 weeks after kidney ischemia-reperfusion injury in mice.
- Fasting suppressed senescence markers p21, Cdkn1a, and Cdkn2a in injured kidney tissue.
- SASP cytokines TNF-α, TGF-β, IL-6, IL-1α, and IL-1β were significantly downregulated by fasting.
- Metabolic regulators SIRT1, phosphorylated AMPK, and PGC-1α were restored by the fasting protocol.
- Results suggest cellular senescence inhibition is a key mechanism behind fasting's kidney-protective effects.
Methodology
Male C57BL/6 mice underwent unilateral ischemia-reperfusion injury and were allocated to a 5:2 intermittent fasting protocol (two 24-hour fasts per week) for eight weeks. Four groups were analyzed: sham, IF only, IRI only, and IF plus IRI. Outcomes included histological fibrosis scoring and molecular analysis of senescence and metabolic markers.
Study Limitations
The study used only male mice, limiting generalizability across sexes and to human populations. A single IRI model was employed, so findings may not extend to other causes of AKI such as sepsis or nephrotoxicity. Direct clinical translation of the 5:2 fasting schedule, particularly in patients with pre-existing kidney dysfunction, requires dedicated human trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: